The title compound is a product of perindopril intramolecular cyclization. It crystallizes in the tetragonal, non-centrosymmetric space group P4 1 2 1 2 (No. 92) with a = 9.3574(2), b = 9.3574(2), c = 45.6369(9) Å, V = 3996.01(14) Å 3 and Z = 8. The crystal consists of one molecule in the asymmetric unit. The packing exhibits weak intermolecular C-H···O=C contacts forming two C(5) and C(10) chains, which together result in graph-set descriptor R 3 3 (18) motif, running along the crystallographic a-axis.
INTRODUCTION
Angiotensin-converting enzyme (ACE) inhibitors are used in therapy of cardiovascular disfunctions. 1 One of the most common ACE inhibitors on the market is perindopril, ((2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2 carboxylic acid (1), used as an antihypertensive drug utilized in the treatment of high blood pressure and heart failure. 2 In the liver and plasma the perindopril is de-esterified by esterases to its active metabolite -the respective diacid -perindoprilat. Contrary to other ACE-inhibitors, it has a higher tissue affinity for the angiotensin-converting enzyme. 3 Clinically useful forms of perindopril are its tert-butylamine (perindopril erbumine) or L-arginine (perindopril L-arginine) salts, which were mentioned for the first time in respective patents a decade ago. 4, 5, 6 Although perindopril was first reported in 1982, 7 no details were given on its crystal structure. However, the crystal structure of perindoprilat solvate with ethanol was revealed in 1991. 8 Also three crystal structures, of a hydrate of perindoprilat, of an erbumine salt and its hydrate have been determined in our laboratory. 9, 10 The cyclization of dipeptides to diketopiperazines is a well-known phenomenon, being a major stability issue of many ACE inhibitors.
11
Perindopril may undergo the appropriate degradation reaction (Scheme) during the manufacturing and formulation processes, which is undesirable due to high toxicity of the product. 12 Now we have determined the crystal structure of the perindopril cyclization product, ethyl (2S)-2-[(3S,5aS,9aS,10aS)-3-methyl-1,4-dioxo-5a,6,7,8,9,9a,10,10a-octahydro-3H-pyrazino [ 
General scheme of perindopril intramolecular cyclization to 1.
EXPERIMENTAL
Well shaped, colourless plate monocrystals suitable for X-ray analysis were grown by slow evaporation from a nitrobenzene solution of the title compound at room temperature.
The crystal structure of (1) was determined by single-crystal X-ray diffraction method from the data collected on the Bruker AXS Smart APEX-II CCD 3-circle diffractometer (equipped with MonoCap capillary). The absorption correction was applied using semi-empirical methods of SADABS program. 13 Data collection and reduction were done with SMART and SAINT-PLUS programs.
14,15 The structure was solved by direct methods and refined by the full-matrix least-squares methods on F 2 with anisotropic thermal parameters for all non-hydrogen atoms to R = 0.0485. All hydrogen atoms were placed in geometrically idealized positions and constrained to ride on their parent atoms with C-H = 0.93 -0.97 Å and with U iso (H) = 1.2 -1.5 U eq (C). The terminal methyl (C14) and ethyl (C18, C19) groups were disordered over two positions. Both parts of the disordered groups were restrained using DFIX with the C-C and C-O distances of 1.525 and 1.430 Å respectively.
A perspective view of the molecular structure of 1 with the atom labels is shown in Figure 1 , while the crystal data are summarized in Table 1 . The configuration of the molecule is all-S. 16 For preparing figures and the geometrical calculations, Mercury and PLATON programs were used. 17, 18 
RESULTS AND DISCUSSION
The title compound (1) crystallizes in the non-centrosymmetric space group P4 1 2 1 2 (No. 92), with one crystallographically independent molecule in the asymmetric unit. The core of the molecule consists of three fused rings, a cyclohexane ring a, a five-membered pyrrolidine ring b and a six-membered diketopiperazine ring c, resulting in a rigid structure. The rest of the molecule is completed by disordered terminal methyl and ethyl groups of alkyl chains, which exist in two equally occupied conformations. Ring a (C3-C8) adopts a slightly deformed chair conformation as indicated by the Cremer and Pople puckering 19 parameters, having a total puckering amplitude Q of 0.527(3) Å with φ = 2.6(12) and θ = 165.9(3)º. Ring b (N1/C1-C3/C8) adopts a slightly deformed half-chair conformation. Its total puckering amplitude Q is 0.399(2) Å and φ = 276.0(3)º. The diketopiperazine ring c (N1/C1-C15/N2/C9-C10) is in a boat conformation with puckering amplitude Q = 0.584(2) Å, φ = 60.9(2) and θ = 92.2(2)º. The two oxygen atoms of carbonyl groups (O1) and (O4) lie on the same side of the pyrrolidine ring. Selected bond lengths and angles with their estimated standard deviations are given in Table 2 .
e-mail: joanna.bojarska@p.lodz.pl A similar geometry is observed in (3S-(2(R*),3α,5αβ,9αβ,10αβ))-decahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)pyrazino(1,2-α)indole-2(1H)-acetic acid ethyl ester methanol solvate (2), which was obtained by cyclization of an other angiotensin-converting enzyme inhibitor -indolapril. 20 The slight difference is visible from superposition of the two structures ( Figure  2 ). The crystal packing of (1) shows two weak intermolecular C-H…..O contacts (Table 3) 
